News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Progenics Pharmaceuticals, Inc. (PGNX) Announces Fourth Quarter And Year-End 2013 Financial Results And Initiates Clinical Development Of Small Molecule Targeted Therapeutic


3/13/2014 8:54:31 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TARRYTOWN, N.Y., March 13, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced its results of operations for the fourth quarter and year-end 2013. The company also announced that it is initiating clinical development of MIP-1095, a PSMA-targeted small molecule radiopharmaceutical for the treatment of prostate cancer.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES